June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The kinase inhibitor SBJ-051 protects mice from light damage and attenuates photoreceptor degeneration in a genetic mouse model of retinitis pigmentosa
Author Affiliations & Notes
  • Pingwu Zhang
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Brendan Lilley
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Stacey Cole
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Cynthia Berlinicke
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Gloria Li
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Derek Welsbie
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Donald J Zack
    Department of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Pingwu Zhang None; Brendan Lilley None; Stacey Cole None; Cynthia Berlinicke None; Gloria Li None; Derek Welsbie Perceive Biotherapeutics, Code C (Consultant/Contractor), Perceive Biotherapeutics, Code F (Financial Support), Perceive Biotherapeutics, Code O (Owner), Perceive Biotherapeutics, Code P (Patent); Donald Zack Perceive Biotherapeutics, Code C (Consultant/Contractor), Neuracle Genetics, Code C (Consultant/Contractor), Spark Therapeutics, Code C (Consultant/Contractor), Perceive Biotherapeutics, Code F (Financial Support), Perceive Biotherapeutics, Code O (Owner), Perceive Biotherapeutics, Code P (Patent)
  • Footnotes
    Support  Foundation Fighting Blindness, National Eye Institute, Research to Prevent Blindness, Edward N. & Della L. Thome Memorial Foundation, Guerrieri Family Foundation
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4890. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pingwu Zhang, Brendan Lilley, Stacey Cole, Cynthia Berlinicke, Gloria Li, Derek Welsbie, Donald J Zack; The kinase inhibitor SBJ-051 protects mice from light damage and attenuates photoreceptor degeneration in a genetic mouse model of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4890.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are characterized by progressive degeneration of photoreceptor (PR) cells. The cause and mechanism of AMD and RP remain incompletely understood. Light damage is a commonly used acute retina degeneration model while retinal degeneration 10 (rd10) mice are a genetic model of retinitis pigmentosa. We previously showed that the mixed-kinase inhibitor SBJ-051 can protect mouse PRs from light damage induced PR injury and cell death (Kim et al., ARVO, 2017, 2019). Here we further define the neuroprotective activity of SBJ-051 in light damaged retinas and also show that it can attenuate PR degeneration in rd10 mice.

Methods : Female BALB/cJ mice (10-week old) were administered 20 mg/kg SBJ-051 by daily intraperitoneal (IP) injection starting either 48 h prior to LD or post LD up to 72 h. Mice were dark-adapted for 12h before exposure to ~4000 lux cool fluorescent light for 4 h, followed by dark recovery for 16h. Rd10 mice (Jackson lab) were injected IP with 20 mg/kg SBJ-051 every other day starting from day 12 until day 35.

Results : In the vehicle injected animals, retinal outer nuclear layer (ONL) thickness decreased 86.5 ± 6.6% two weeks post LD based on SD-OCT. In the animals injected IP with SBJ-051 starting prior to LD, there were no statistically significant changes in ONL thickness post LD. In the animals receiving SB-051 starting post LD (14h), ONL thickness only decreased 7.6 ± 4.5%. A-wave and b-wave maximal amplitudes were also significantly preserved with SBJ-051 treatment post LD (a-wave: 70.2 ± 9.7%, b-wave: 64.5 ± 15.3%; P<0.05). Preliminary data suggests that SBJ-05 can also partially protect PRs in the rd10 model. ONL thickness in the SBJ-051-treated group on day 28 showed 48.5 ± 3.9% thickness compared to that on day 14, while the vehicle group showed 25.5% of ONL thickness (P<0.05). Electroretinogram (ERG) and immunohistochemical analysis of rd10 mice are in process.

Conclusions : Administration of the kinase inhibitor SBJ-051 either before or after LD protects mouse retinas from photochemical damage and attenuates ONL thinning in the rd10 mouse RP model. These findings suggest that PR protection through treatment with SBJ-051, or a related molecule, may be a promising therapeutic strategy for human retinal degeneration.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×